PolyPid Ltd. (PYPD) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

PolyPid Ltd.

PYPD

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

30M

Biotechnology

Next Earning date - 06 May 2025

30M

Biotechnology

Next Earning date - 06 May 2025

2.95USD

0.12 ( 4.20%)

Market Open

Relative Strenght

39

Volume Buzz

-42%

Earning Acce

Yes

Dist 52w H.

46%

Quote Panel

Updated March 24, 2025

1W 0.26 % 1M 0.94 % 3M 4.13 % 1Y -38.69 %

Key Metrics

Market Cap
30.24M
Shares Outstanding
10.19M
Share in Float
5.69M
Dividende
0

Earning Date
06 May 2025
Price Target
2.9676
Average Volume
23300
Beta
1.273

Range
2.37-5.5
Industry
Biotechnology
Website
https://www.polypid.com
Sector
Healthcare

Fundamentals

Relative Strength

PYPD

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$3M

NaN%

2025-Revenue

$2.40

NaN%

2025-EPS

0

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

0

Last analyst upgrade/downgrade

Craig-Hallum

initialise

Previous: Not converted

2024-11-04

Now: Buy

Raymond James

downgrade

Previous: Not converted

2022-09-06

Now: Outperform

Guggenheim

upgrade

Previous: Not converted

2022-09-02

Now: Neutral

Earnings Growth

YoY

Current

Estimates

Q1.23

N/A

-8.41
vs -18.92

Q2.23

N/A

-3.90
vs -18.32

Q3.23

N/A

-3.40
vs -14.41

Q4.23

N/A

-3.97
vs -9.61

Q1.24

N/A

-1.37
vs -8.41

Q2.24

N/A

-1.25
vs -3.90

Q3.24

N/A

-1.22
vs -3.40

Q4.24

N/A

NA
vs -3.97

Q1.25

N/A

-0.88
vs -1.37

Q2.25

N/A

-0.69
vs -1.25

Sales Growth

YoY

Current

Estimates

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

NA vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Q3.24

NA

NA vs NA

Q4.24

NA

NA vs NA

Return on Equity

QoQ

Q1.23

-53%

-0.53
vs -1.11

Q2.23

-70%

-0.70
vs -0.53

Q3.23

-158%

-1.58
vs -0.70

Q4.23

+303%

3.03
vs -1.58

Q1.24

-90%

-0.90
vs 3.03

Q2.24

-393%

-3.93
vs -0.90

Q3.24

-360%

-3.60
vs -3.93

Q4.24

-111%

-1.11
vs -3.60

Institutionnal Ownership

QoQ

Q3.21

19

19
vs 22

-14%

Q4.21

30

30
vs 19

58%

Q1.22

31

31
vs 30

3%

Q2.22

30

30
vs 31

-3%

Q3.22

21

21
vs 30

-30%

Q4.22

14

14
vs 21

-33%

Q1.23

10

10
vs 14

-29%

Q2.23

13

13
vs 10

30%

Earnings Growth

Latest News

PYPD

globenewswire.com

7 hours ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PYPD

globenewswire.com

7 hours ago

PolyPid to Participate in the 37th Annual ROTH Conference

PYPD

globenewswire.com

7 hours ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PYPD

globenewswire.com

7 hours ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PYPD

globenewswire.com

7 hours ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

PYPD

seekingalpha.com

10 hours ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript